Key Takeaways from #ESMO20 on Thoracic Malignancies

Key Takeaways from ESMO: Adjuvant and Neoadjuvant Therapy for NSCLC

Jean-Yves Douillard

1. What did we learn about targeted therapy and adjuvant therapy for lung cancer at this conference?
2. What did the updated results from ADAURA presented at ESMO focus on?
3. Are there any other data on targeted agents in the adjuvant setting for NSCLC that you’d like to highlight?
4. What about the neoadjuvant setting using immunotherapy?
5. Were there any data on radiation therapy in the adjuvant setting for NSCLC presented at ESMO?

Key Takeaways from ESMO: Updates on Small-Cell Lung Cancer

Jean-Yves Douillard

1. What are the most impactful studies at this year’s ESMO pertaining to the use of immunotherapy in small-cell lung cancer?
2. How is the high-dose twice-daily dose of radiation tolerated in patients with small-cell lung cancer?
3. What other trials at this year’s ESMO were practice-informing in small cell lung cancer?
4. How do the updated results of the CASPIAN trial, also presented at ESMO, add to these?
5. Was there quality of life data presented on the addition of immunotherapy to conventional platinum-based chemotherapy in extensive small-cell lung cancer?